Efficacy, durability, and response predictors of low-dose interleukin-2 therapy for chronic graft-versus-host disease. - Wikidata - awgldk - TriplyDB

Efficacy, durability, and response predictors of low-dose interleukin-2 therapy for chronic graft-versus-host disease.

Efficacy, durability, and response predictors of low-dose interleukin-2 therapy for chronic graft-versus-host disease.

http://www.wikidata.org/entity/Q37076418

about

The CXCL10/CXCR3 Axis and Cardiac Inflammation: Implications for Immunotherapy to Treat Infectious and Noninfectious Diseases of the Heart Regulatory T Cell Responses in Participants with Type 1 Diabetes after a Single Dose of Interleukin-2: A Non-Randomised, Open Label, Adaptive Dose-Finding Trial An activated Th17-prone T cell subset involved in chronic graft-versus-host disease sensitive to pharmacological inhibition.In vivo kinetics and nonradioactive imaging of rapidly proliferating cells in graft-versus-host disease IL-2 promotes early Treg reconstitution after allogeneic hematopoietic cell transplantation.Manipulation of Innate and Adaptive Immunity through Cancer Vaccines.IL-2, the next best thing in chronic GVHD therapy?Autophagy-dependent regulatory T cells are critical for the control of graft-versus-host disease.Low-dose IL-2 selectively activates subsets of CD4+ Tregs and NK cells.Tregs: hype or hope for allogeneic hematopoietic stem cell transplantation?Treg-Centric View of Immunosuppressive Drugs in Transplantation: A Balancing Act.Low-Dose IL-2 in the Treatment of Lupus.Chronic graft-versus-host disease: biological insights from preclinical and clinical studies.Mechanistic approaches for the prevention and treatment of chronic GVHD.Novel targets in the treatment of chronic graft-versus-host disease.Harnessing bone marrow resident regulatory T cells to improve allogeneic stem cell transplant outcomes.PD-1 modulates regulatory T-cell homeostasis during low-dose interleukin-2 therapy.Prophylactic use of low-dose interleukin-2 and the clinical outcomes of hematopoietic stem cell transplantation: A randomized study.Low-dose interleukin-2 as a modulator of Treg homeostasis after HSCT: current understanding and future perspectives.Efficacy and tolerance of ruxolitinib in refractory sclerodermatous chronic graft-versus-host disease.New and emerging therapies for acute and chronic graft versus host disease.Application of proteomics to graft-versus-host disease: from biomarker discovery to potential clinical applications.Low CD25 on autoreactive Tregs impairs tolerance via low dose IL-2 and antigen delivery.SJS/TEN 2017: Building Multidisciplinary Networks to Drive Science and Translation.Cytokine mediators of chronic graft-versus-host disease.Gene Therapy With Regulatory T Cells: A Beneficial Alliance.Advances in the Use of Regulatory T-Cells for the Prevention and Therapy of Graft-vs.-Host Disease.

P2860

Q28079006-3C2CD0CE-D372-4567-BF95-C111558194C1 Q28554636-0D0FE98F-2D0F-413A-A79A-0EE4E89645AA Q33798102-3AB2C393-F5D8-4A88-8A2F-F616BFB84811 Q33798249-CDD04750-40FD-48C2-B392-FC4A7FCFF98C Q33816022-FA7AFE25-F020-411D-8FC8-56D20625BA25 Q34552791-6DBEFC2F-8A53-49E2-AC3A-AF6FA03F958C Q37076414-CA82C619-B319-4224-A432-C5717BBB34E3 Q37277015-4E6C6A4E-4077-4F92-8F76-7B5058218527 Q37377103-909858A3-BE58-45D8-9D38-F338122C6DBB Q38742863-32F78DC0-CF82-4E31-AEA1-7CBA62225469 Q38942832-455C2D8B-02A2-4525-AEEE-0276639E511A Q38979253-D9633A36-E69F-48D2-A198-2CE27673C58B Q39002164-FE404CF8-71CF-47B5-BB81-E6C7EBC41D77 Q39002166-E22A9DA2-DAF3-4583-BBE8-77B6304E897D Q39023963-F2C52B2F-BCB1-429E-B7C3-880A64CB57FC Q39036180-AA00F2C0-5314-4CF4-BDE5-60D3EFDAC398 Q40354412-5F49310A-8F3E-4F5B-B73E-408C9A45B5B4 Q42968779-9FBB729C-8D29-43F8-BA35-AC47ACFB815C Q47578102-B0A0ACFC-C1E4-4023-BD29-B93023612BD7 Q48259698-D027A174-C3A2-4AA8-89DE-9068BA3F2C85 Q49238507-1E08CB24-092D-4CDE-A8A0-25C5F736CB73 Q49645938-3A524A4D-8249-41AB-B70C-C198E8DDAA9C Q50030501-5F30579B-4CF9-4774-AD38-454006F61ADB Q50115047-14518547-3BB0-4AF1-B176-4AFB9D57C8B6 Q50915048-6AC22797-3EEA-4B02-9178-3774D3F5F91A Q52721830-E64E10BF-99E0-4E0B-92DC-847FE471A33A Q52769264-3858F6C7-2224-46D9-9D73-EFCAB37066C2

P2860

Efficacy, durability, and response predictors of low-dose interleukin-2 therapy for chronic graft-versus-host disease.

http://www.wikidata.org/entity/Q37076418

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 12 April 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Efficacy, durability, and resp ...... nic graft-versus-host disease.

@en

Efficacy, durability, and resp ...... nic graft-versus-host disease.

@nl

type

label

Efficacy, durability, and resp ...... nic graft-versus-host disease.

@en

Efficacy, durability, and resp ...... nic graft-versus-host disease.

@nl

prefLabel

Efficacy, durability, and resp ...... nic graft-versus-host disease.

@en

Efficacy, durability, and resp ...... nic graft-versus-host disease.

@nl

P1433

Q37076418-5E05F316-8BA5-4635-B853-35D575BCEE82

P1476

Q37076418-4C383407-9B19-4350-9EAA-AD606713C3F8

P2093

Q37076418-10E0CA3D-1C46-4821-91AC-2D495C79A12C

Q37076418-1B9E01D9-BB30-48F8-8E8F-207F68BAC756

Q37076418-2F643D8F-7036-4EE0-9D93-260462E50B07

Q37076418-513DBD41-B922-425C-9EB3-CCC09635AD16

Q37076418-599CF4AD-B6E0-4F32-8DA7-E90828DEC0E7

Q37076418-5ADEA408-061D-4F5F-9764-46898AFF2B31

Q37076418-5BB339E6-9BE6-4A47-8412-9DE12845BE03

Q37076418-62830606-28E8-4E9D-B3F4-9ADD7908F4C2

Q37076418-700A5D30-342D-4D53-8B0C-E7F2AACAD4D1

Q37076418-869EB30C-3AD3-44EC-8250-2DBE7AF99581

P2860

Q37076418-038D79A9-87F2-4953-82BC-28BF68A2F315

Q37076418-08FBC72B-49DD-4322-9A72-C1B0DF225EB8

Q37076418-0BCDCA34-E4AF-4B1E-9488-E669B7CBEEF2

Q37076418-151DC78D-958B-4990-B069-2D2B55A349AE

Q37076418-28A3075B-7022-4EAC-B723-99A3C4802ABB

Q37076418-2C0D0316-B1F7-4377-81F1-A5DD54BF4BE1

Q37076418-2E1789F4-A4EA-4879-B82E-C7B589DA1D1C

Q37076418-3948BA23-FA36-43ED-9AB4-41F00FF116CA

Q37076418-39E48AE3-83E5-47CA-BDE5-635D554B9605

Q37076418-419CAF79-A513-4EC5-85BB-66FFF456365F

P304

Q37076418-2F2185B9-9EDF-4169-BF15-1D7F29246034

P31

Q37076418-A2785761-7E29-4F8C-9A6E-D3C4241C2817

P356

Q37076418-0066C5B5-AEF9-42CB-A9E9-1E597D95AE96

P407

Q37076418-0D961A9C-0E0C-4BBD-8AE4-8161612A2528

P433

Q37076418-D0095707-F50D-4B49-9B35-8A3C9B508A88

P478

Q37076418-9D67624B-9ECB-4946-9B08-9F10845FD164

P50

Q37076418-56B42556-E6B3-4E88-914E-E31B12433C61

P577

Q37076418-2F05CFDD-2B15-403A-B5F5-BFDB7F8728BF

P698

Q37076418-27FB5048-0262-490B-87F7-EB48B5ADDD13

P921

Q37076418-acda1a51-6989-4b78-ba9e-631df98b842e

P932

Q37076418-9138A6EF-F59D-4B34-9849-3BBC0152DB10

P356

BLOOD-2016-02-702852

P1433

P1476

Efficacy, durability, and resp ...... nic graft-versus-host disease.

@en

P2093

Carol G Reynolds

http://www.w3.org/2001/XMLSchema#string

Corey S Cutler

http://www.w3.org/2001/XMLSchema#string

David Avigan

http://www.w3.org/2001/XMLSchema#string

Edwin P Alyea

http://www.w3.org/2001/XMLSchema#string

Haesook T Kim

http://www.w3.org/2001/XMLSchema#string

Jennifer Whangbo

http://www.w3.org/2001/XMLSchema#string

Jerome Ritz

http://www.w3.org/2001/XMLSchema#string

John Koreth

http://www.w3.org/2001/XMLSchema#string

Joseph H Antin

http://www.w3.org/2001/XMLSchema#string

Katherine Dusenbury

http://www.w3.org/2001/XMLSchema#string

P2860

CD4+CD25+ T(R) cells suppress innate immune pathology through cytokine-dependent mechanisms

CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production

Altered regulatory T cell homeostasis in patients with CD4+ lymphopenia following allogeneic hematopoietic stem cell transplantation.

Patient-reported quality of life is associated with severity of chronic graft-versus-host disease as measured by NIH criteria: report on baseline data from the Chronic GVHD Consortium

Ultra-low dose interleukin-2 promotes immune-modulating function of regulatory T cells and natural killer cells in healthy volunteers.

Current issues in chronic graft-versus-host disease.

Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics.

Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation.

National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report.

Mechanisms of impaired regulation by CD4(+)CD25(+)FOXP3(+) regulatory T cells in human autoimmune diseases

P304

130-137

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2016-02-702852

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

128

http://www.w3.org/2001/XMLSchema#string

P50

P577

2016-04-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27073224

http://www.w3.org/2001/XMLSchema#string

P921

P932

4937358

http://www.w3.org/2001/XMLSchema#string